Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

NCT05304715 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Clostridioides Difficile Infection
Stool Microbiome
Organ Dysfunction Syndrome
Clostridioides Difficile Infection Recurrence
Mortality

Interventions

DRUG: Bezlotoxumab
DRUG: Normal saline 0.9% or 5% dextrose water

Sponsor

Hellenic Institute for the Study of Sepsis